Aberrant enhancer hypomethylation contributes to hepatic carcinogenesis through global transcriptional reprogrammingLei Xiong, Ka‐Fai To, Feng Wu et al.|Nature Communications|2019Cited by 105
Efficacy of Onalespib, a Long-Acting Second-Generation HSP90 Inhibitor, as a Single Agent and in Combination with Temozolomide against Malignant GliomasAlessandro Canella, Vinay K. Puduvalli, Alessandra M. Welker et al.|Clinical Cancer Research|2017Cited by 69
Integrative analysis identifies targetable CREB1/FoxA1 transcriptional co-regulation as a predictor of prostate cancer recurrenceBenjamin Sunkel, Qianben Wang, Dayong Wu et al.|Nucleic Acids Research|2017Cited by 12
Data from Efficacy of Onalespib, a Long-Acting Second-Generation HSP90 Inhibitor, as a Single Agent and in Combination with Temozolomide against Malignant GliomasAlessandro Canella, Vinay K. Puduvalli, Alessandra M. Welker et al.|Unknown|2023Cited by 0
Data from Efficacy of Onalespib, a Long-Acting Second-Generation HSP90 Inhibitor, as a Single Agent and in Combination with Temozolomide against Malignant GliomasAlessandro Canella, Vinay K. Puduvalli, Alessandra M. Welker et al.|Unknown|2023Cited by 0